3-(3-Biphenyl)-4-cyano-5-(isopropylthio)thiophene-2-carboxylic acid (1aa) | 1421348-22-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-Biphenyl)-4-cyano-5-(isopropylthio)thiophene-2-carboxylic acid (1aa)
• 英文别名: 4-cyano-3-(3-phenylphenyl)-5-propan-2-ylsulfanylthiophene-2-carboxylic acid
• CAS: 1421348-22-2
• 化学式: C₂₁H₁₇NO₂S₂
• 分子量: 379.503
• InChiKey: RXUGWQMMKWZWQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S)-2-氨基-4-甲硫基丁酸甲酯 、 3-(3-Biphenyl)-4-cyano-5-(isopropylthio)thiophene-2-carboxylic acid (1aa) 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-methyl 2-(3-(biphenyl-3-yl)-4-cyano-5-(isopropylthio)thiophene-2-carboxamido)-4-(methylthio)butanoate
  参考文献：
  名称：

  在3-芳基噻吩上引入甲硫氨酸模拟物：对蛋白质法呢基转移酶抑制和抗寄生虫活性的影响†

  摘要：

  在我们寻找具有抗寄生虫活性的新的蛋白质法呢基转移酶抑制剂的过程中，我们发现在3-芳基噻吩的2位添加甲硫氨酸残基可以大大改善酶的抑制作用。为了研究此蛋氨酸残基对FTase和抗寄生虫活性的影响，研究了29个新型的四取代噻吩蛋氨酸或类似的部分被合成。对人和布鲁氏锥虫蛋白法呢基转移酶以及4种原生动物寄生虫的增殖评估了这些新衍生物：恶性疟原虫，布鲁氏锥虫，克鲁氏锥虫和利什曼原虫。一些化合物在T.b上显示出有希望的低微摩尔或亚微摩尔活性。Brucei和L. donovani证实了这一新类别作为抗寄生虫药的潜力。

  DOI：

  10.1039/c3md00065f
• 作为产物：
  描述：

  C₂₂H₁₈NO₂PolS₂ 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 以76%的产率得到3-(3-Biphenyl)-4-cyano-5-(isopropylthio)thiophene-2-carboxylic acid (1aa)
  参考文献：
  名称：

  New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis

  摘要：

  A new synthetic pathway was devised to reach tetrasubstituted 3-arylthiophene 2-carboxylic acids in a three-step solid-phase synthesis. This very efficient methodology provided more than 20 new compounds that were evaluated for their ability to inhibit protein farnesyltransferase from different species as well as Trypanosoma brucei and Plasmodium falciparum proliferation.

  DOI：

  10.3109/14756366.2011.643302

文献信息

• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160303146A1

  公开（公告）日：2016-10-20

  This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160375041A1

  公开（公告）日：2016-12-29

  The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• [EN] INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS<br/>[FR] INHIBITION DE VOIES DE BIOSYNTHÈSE D'ISOPRÉNOÏDES POUR TRAITER DES TROUBLES AUTO-IMMUNS
  申请人：TABACZYNSKI DAVID A

  公开号：WO2015084721A1

  公开（公告）日：2015-06-11

  The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• [EN] INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS<br/>[FR] INHIBITION DE VOIES DE BIOSYNTHÈSE D'ISOPRÉNOÏDES POUR TRAITER DES TROUBLES NEURO-INFLAMMATOIRES
  申请人：TABACZYNSKI DAVID A

  公开号：WO2015089349A1

  公开（公告）日：2015-06-18

  This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.